Breast cancer is still the leading cause of cancer deaths among women worldwide, and new therapies to treat this dangerous disease are desperately needed. The serendipitously found anticancer drug cisplatin and its second-generation congener carboplatin appear to be promising drug systems for the treatment of breast tumors, in particular of multidrug resistant and highly aggressive triple-negative subtypes. In the wake of these platinum drugs, complexes of the coinage metals copper, silver, and gold were developed that showed enhanced selectivity for breast cancer while causing fewer and weaker side-effects. This review takes stock of the latest developments in the field of coinage metal anticancer drugs with an emphasis on their biological and mechanistic aspects. Pertinent literature is covered up to 2012.